Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive vs Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients
NCT03510078Completed
- Sponsor
- Rabin Medical Center
- Start
- Apr 2018
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Randomised trial of human insulin in type 2 diabetes mellitus (T2DM) and hyperglycemia (2 arms), sponsored by Rabin Medical Center. Primary endpoint: Composite outcome of mortality, severe hypoglycemia, severe infections, CVA, and cardiac ischemic events at 30 days. Started Apr 2018; status: completed.
02
Drugs
human insulin
03
Conditions
type 2 diabetes mellitus (T2DM)hyperglycemia
Beyond the preview
Go deeper on NCT03510078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510078.